Targets › PFATP4
1 program from 1 company in 2 trials: 2 Phase 2; Infectious disease; next expected readout Feb 2027.
Open in Phaseline: the race on PFATP4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Cipargamin (KAE609) P-type ATPase inhibitor | PFATP4 | Phase 2 | Uncomplicated Plasmodium Falciparum Malaria | Feb 2027 |
Uncomplicated Plasmodium Falciparum Malaria (2)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.